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Purpose: To evaluate the changes in lipid and lipoprotein 
patterns in adult patients with haematological cancers with 
any possible risk of cardiovascular event. 
Patients and Methods: The clinico-pathological types of 
haematological cancers, body mass index and ages of the of 
all 74 haematological cancer patients attending University of 
Benin Teaching Hospital, Benin City, Nigeria between 
January 2005 and September 2008 were evaluated. The 
serum lipid and liporprotein levels of the blood samples 
collected from the patients were assayed. The data were 
analysed and compared statistically with those of 45 health 
control subjects.  
Results: The mean serum total cholesterol and low density 
lipoprotein in the patients (2.5±1.0mmol/l and 1.5±1.0mmol/l) 
were significantly lower than those of controls (4.1±1.1mmol/l 
and 2.4±1.1mmol/l), respectively (p=0.0004). However, the 
mean serum triglyceride of the patients was significantly 
higher than the controls (p=0.007). 
Conclusion: Patients presenting with haematological 
malignancies have reduced levels of total serum cholesterol 
and LDL-cholesterol but elevated level of serum triglyceride.   
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Introduction 
 
Abnormal blood lipid profile have been found 
to be associated with cancer [1]. This 
abnormality is a common feature of both 
haematological malignancies and solid 
tumors.
1
 The success of cancer 
chemotherapy is dependent on the ability to 
utilize biological differences between 
malignant and normal cells to selectively 
destroy the tumor cells [2]. One such 
difference that has been reported is that of 
the receptor-mediated cellular uptake of low 
density lipoprotein (LDL)
 
[2]. Many studies 
have reported a return to normal values of 
lipid profile after effective chemotherapy [1]. 
Previous studies have found that certain 
malignant cell types have elevated LDL 
receptor activity and that the possibility of 
LDL consumption by tumor cells causes 
hypocholesterolaemia [3]. An inverse relation 
between plasma cholesterol and the 
occurrence of cancer has also been 
indicated [3]. Lipid parameters are therefore 
considered as reliable markers of complete 
remission and may be useful in the follow up 
of cancer patients [1]. However, there is 
paucity of information on the role and the 
profile of lipids and lipoprotein levels in 
haematological malignancies seen in 
Africans.  
 
In this study, the profile of serum lipids in 
haematological cancer patients was 
examined with the aim of elucidating the type 
of lipoprotein disorders associated with the 
cancers. This is aimed at evaluating the 
changes in lipid pattern and the possible risk 
of cardiovascular event in adult patients with 
haematological cancers. 
 
Patients and Methods 
 
All patients with haematological malignan-
cies attending the Oncology clinics and those 
admitted to in the Medical wards of the 
University of Benin Teaching Hospital 
(UBTH), Benin City, Nigeria were 
prospectively studied (July 2007-December 
2008). The clinico-pathological types of 
haematological cancers, the ages of the 
patients, anthropometric indices (body mass 
index, BMI), and lipid and lipoprotein levels 
(LPA) of the patients were analysed. The 
various haematological malignancies were 
diagnosed based on typical clinical features, 
standard cytomorphological and histological 
findings including type-specific diagnostic 
criteria. The BMI at baseline and at each 
respective age was calculated using the 
formula: weight (in kilograms) at the given 
age divided by baseline height squared (in 
meters). BMI ≤19 was considered 
underweight, 20-25 normal weight, 26-29 
overweight and ≥30 obesity [4]. The blood 
lipid and lipoproteins assayed include serum 
total cholesterol (TC), triglyceride (TG), low 
density lipoprotein-cholesterol (LDL-C) and 
high density lipoprotein-cholesterol (HDL-C). 
The LPA levels of 74 apparently healthy age-
and-sex matched subjects without any 
history of clinical disorders and having no 
diseases that could affect the blood lipid 
profile served as controls.  
 
Clinico-pathological and LP levels were 
analyzed after adjusting for age, cigarette 
smoking, alcohol ingestion, hypertension and 
diabetes mellitus. The Ethical committee of 
the hospital granted approval for the study 
and informed consent was obtained from all 
patients. Patients received appropriate 
cytotoxic therapy for their type of 
haematological malignancies. 
 
Laboratory and Lipid assay 
 
The subjects were fasted overnight (12-14 
hours) and 10 ml of venous blood was 
obtained from the antecubital veins after 
routine aseptic procedure. The LPA was 
assayed using already standardized and well 
established methodologies.
5-8
 All assays 
were performed using kits manufactured by 
Human Diagnostic Laboratory (Wiesbaden, 
Germany). Total cholesterol (TC) was done 
using the modified Liebermann-Burchards 
method of Abell et al [5], and high density 
lipoprotein-cholesterol (HDL-C) by precipita-
tion method [6]. Triglyceride (TG) was 
assayed using enzymatic colorimetric 
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method after hydrolysis of the TG [7]. Low 
density lipoprotein-cholesterol (LDL-C) was 
calculated by indirect method using 






CHDLTCCLDL −−−=−  
The current Adult Treatment Panel (ATP) III 
[8] in comparing the values was adopted and 
all concentrations were given in millimoles 




Statistical multivariate analysis of data 
obtained was performed using Instat Graph 
Pad software version 2.05a. Means and SD 
were determined for quantitative data and 
frequency determined for categorical values. 
At 95% confidence interval, any 2-tailed p value 




A total of 74 consecutive patients with 
hematological cancers were seen during the 
study. This comprised 46 males (62.2%) and 
28 females (37.8%) with a male-to-female 
ratio of 1.6:1. These were compared with 45 
non-cancer apparently healthy controls (25 
males and 20 females) who were pre-
screened and found without any history of 
clinical disorder. The mean age of the 
patients’ was 49.2±15.9 yr with a median age 
of 55 yr (range, 18-80 yr).  
 
The haematological malignancies consisted 
of 32 (43.2%) chronic leukaemias (18 
chronic myeloid leukaemia (CML), 12 chronic 
lymphocytic leukaemia (CLL) and 2 hairy cell 
leukaemia, HCL); 18 (24.3%) lymphomas (12 
non Hodgkin’s lymphoma, NHL and 6 
Hodgkin’s lymphoma, HL); 12 (16.2%) 
multiple myeloma; 10 (13.5%) acute 
leukaemia (6 acute lymphoblastic leukaemia, 
ALL and 4 acute myeloblastic leukaemia, 
AML); and 2 (2.7%) had aplastic anemia. 
Lymphoma and chronic leukaemias were the 
most common haematological cancers seen.  
The results of total serum lipid and 
lipoprotein levels of the cancer patients 
combined compared with controls are shown 
in Table 1. Mean basal levels of TC and 
LDL-C of the patients was significantly lower 
than the mean basal level observed in the 
controls (p<0.001). TG of the cancer patients 
was significantly higher than that observed in 
controls (p=0.007). The ratio of TC to HDL-C 
in cancer patients was 2.5 compared to the 
control value of 3.5. The TG to HDL-C ratio, 
which is a predictor of coronary events, was 
3.3. There was no significant difference in 
mean BMI between the controls and the 
patients (p>0.05) and majority of the patients 
(56.8%) were within the normal weight 
category while 6.76% were obese.   
 
The overall mean serum lipid and lipoprotein 
levels in the different haematological cancers 
including chronic leukaemia, lymphomas and 
multiple myeloma compared with controls is 
shown in Table 2. TC and LDL-C of chronic 
leukaemia patients was significantly lower  
 
 
Table 1: The mean serum lipid and lipoprotein findings of combined haematological 




(n=74)                 
Control value 
(n=45)                    
P value 
Total cholesterol (mmol/l)       2.7±41.1  4.1±1.1 <0.0001 
Triglyceride (mmol/l)           1.6±0.8 1.2±0.4    0.007 
LDL-C (mmol/l)                 1.5±1.0                         2.4±1.1                                0.0004
HDL-C (mmol/l)                             1.1±0.7               1.2±0.3 ns 
BMI (kg/m
2
)                                           23.0±3.4                      23.9±4.2       ns 
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Table 2: The mean serum lipid and lipoprotein findings in controls, chronic 
leukaemia, lymphomas and multiple myeloma 
 
Parameters                                  Haematological       Controls (n=45)    P values               
                                                     cancers                        
               Chronic leukaemia (n=32)  
Total cholesterol (mmol/l)    2.5±1.0  4.1±1.1  <0.0001 
Triglyceride (mmol/l)           1.6±0.8        1.2±0.4         0.0036 
LDL-C (mmol/l)      1.6±0.8  2.4±1.0 0.0007 




Total cholesterol (mmol/l)    3.7±1.1    4.1±1.1    ns 
Triglyceride (mmol/l)        2.0±0.8             1.2±0.4     0.0003 
LDL-C (mmol/l)                             1.8±1.4   2.4±1.0           ns 
HDL-C (mmol/l)      1.2±0.8            1.2±0.3          ns 
 
Multiple myeloma (n=12) 
 
Total cholesterol (mmol/l)               1.9±0.8  4.1±1.1                   <0.0001 
Triglyceride (mmol/l)                1.3 ±0.6  1.2±0.4                   ns 
LDL-C (mmol/l)                 0.9±0.7  2.4±1.0                   0.0003 
HDL-C (mmol/l)                     1.1±0.6                 1.2±0.3                   ns 
 
 
than in controls while TG was higher than the 
values seen in controls (p=0.0036). The 
lymphoma patients only showed a significant 
increase in TG when compared with the 
controls (p=0.0003). In multiple myeloma 
patients, TC and LDL-C values were 





The risk associations between lipid/ 
lipoprotein levels and different types of 




between high cholesterol levels and 
increased risk of cancer has been an 
interesting area of investigation because the 
pathway for cholesterol synthesis may 
produce various tumorigenic compounds and 
because cholesterol serves as a precursor 
for the synthesis of many sex hormones 
linked to increased risk of various cancers.
10
 
The findings in this study could therefore 
serve to determine the pattern of lipid profile 
in order to evaluate whether there is a 
possible risk factor. 
 
It was hypothesized that there could be 
hypercholesterolaemia and hyperlipoprotein-
aemia in haematological cancer patients 
seen in Nigeria as hypercholesterolaemia is 
a risk factor for coronary events in older men 
and women.
L5
 However, in considering TC 
and LDL-C as lipid risk factors, 
hypocholesterolaemia and hypolipoprotein-
aemia were found, suggesting that there is 
no risk of cardiovascular disorders in these 
patients compared with normal individual. 
This is similar to Ishibashi findings of 
hypolipid in haematologic disorders [11]. The 
hypocholesterolaemia in cancer patients may 
be caused by the possibility of elevated LDL-
C receptor activities in the malignant cells 
[3]. During a chemotherapy regimen in a 
CML patient a reciprocal relation between 
LDL-C levels and the degree of leucocytosis 
and splenomegaly was found [12]. It was 
reported that tumor load, presence of an 
enlarged spleen and changes in lipid 
metabolism of circulating cells contributed to 
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the reduction in LDL-C levels leading to the  
hypolipoproteinaemia.  
 
The association between haematological 
cancer/solid tumors and blood lipid/ 
lipoprotein profile has been reported to be 
altered [13,14]. Abnormal lipoproteins as 
shown by agarose gel electrophoresis has 
been reported as far back as 70 yr ago in 
multiple myeloma where presence of extra 
lipoprotein fractions was shown [15]. The 
haematological cancer patients studied with 
the exception of patients with lymphoma, 
showed significantly lower TC, LDL-C and 
HDL-C than age-and-sex matched non-
cancer subjects along with high levels of 
serum TG. These are similar to the findings 
of Fiorenza et al [13] that the lowest values 
of TC, LDL-C and HDL-C are found in 
haematological cancer patients. They 
reported that the abnormality which is a 
common feature of both haematological and 
solid tumors is not entirely explained by poor 
nutrition. This is corroborated by the non 
significant BMI levels found in our patients. 
Cerhan et al in a study also found no 
evidence that height, weight, body mass or 
physical activity play important roles in NHL 
in particular.
16
 However, in other studies 
several anthropometric measures, including 
body mass
17
 and height [18] have been 
suggested as NHL risk factors. 
  
The high lipid levels and their ratios may 
pose a threat by predisposing the cancer 
patients to coronary events which may 
contribute to mortality. The TC: HDL-C ratio 
of 2.5 suggests that these patients are not 
exposed to higher risk than normal people; 
but the TG: HDL-C ratio which is a strong 
predictor of future coronary events was 3.3, 
showing the potential high risk to the 
patients. This could have arisen from the 
combined grouping of the cancer patients at 
the different disease stage. According to 
Foder et al
19
 in their study on target lipid 
values and risk level, they suggested that 
patients’ values should be kept below 4 in 
very high-risk patients.  
The decrease HDL-C found in this study is 
similar to the observation of another study 
which demonstrated that decrease in HDL-C 
is dependent on disease stage [20]. 
However, updated National Cholesterol 
Education Program Adult Treatment Panel III 
guidelines emphasize that a low level of HDL 
alone or in association with hypertrigly-
ceridemia increases the risk of cardio-
vascular disease [21], but our patients had 
low, non significant level of HDL-C. This 
supports current understanding that HDL-C 
exerts antiatherogenic effect by transporting 
cholesterol from peripheral tissues back to 
the liver for excretion.  Hypertriglyceridaemia 
found in our cancer patients has been 
implicated as an increased risk factor in 
coronary artery disease (CAD) development; 
but the increased triglyceride is said to be a 
risk factor that is modifiable with health 
education and dietary controls. The total 
lipaemia and lipoprotein fraction alterations 
observed in a study make the diagnostic 
value of atherosclerotic threat in patients with 
CLL doubtful with the use of this parameters 
[20]. 
     
Lipid lowering agents for LDL-C has been 
repeatedly shown in large clinical trials to 
improve survival dramatically and reduce 
cardiac events in both primary and 
secondary prevention.
22
The patients though 
few in number were not prone to 
cardiovascular events since we did not find 
elevated level of TC and LDL-C. The V-
shaped associated between LDL-C and 
cancer risk suggests multiple mechanisms 





Patients presenting with haematological 
malignancies have reduced levels of total 
serum cholesterol and LDL-cholesterol but 
elevated level of serum triglyceride. We 
however advocate the assessment of lipid 
profile regularly in patients with 
haematological malignancies. 
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